Cell Based Assays Global Market Report 2021: COVID-19 Growth And Change To 2030

Cell Based Assays Global Market Report 2021: COVID-19 Growth And Change To 2030

  • September 2021 •
  • 175 pages •
  • Report ID: 6151592 •
  • Format: PDF
Major players in the cell based assays market are Thermo Fisher, Danaher, Becton, Dickinson and Company, GE Healthcare, and Merck.

The global cell based assays market is expected to grow from $17.49 billion in 2020 to $19.29 billion in 2021 at a compound annual growth rate (CAGR) of 10.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $26.69 billion in 2025 at a CAGR of 8.5%.

The cell based assays market consists of sales of cell based assays.Cell-based assays are analytical tools that are designed to study a mechanism or process of cellular function.

Companies developing cell based assays provide consumables such as reagents, assays kits and microplates as well as instruments, services and software. This report includes sales of reagents, cell lines, microplates, microplate, assay kits, probes and labels, and others.

The cell based assays market covered in this report is segmented by product & service into consumables, instruments, services, software. It is also segmented by application into drug discovery, basic research, ADME studies, predictive toxicology, others; by end user into pharmaceutical and biotechnology companies, academic and government research institutes, contract research organizations (CRO), other end users; by technology into automated handling, flow cytometry, label-free detection, high-throughput screening, others; by consumables into reagents and media, cells and cell lines, probes and labels and by instruments into microplates, microplate readers, high throughput screening, liquid handling systems.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

High cost of instruments is the major factor restraining the global cell based assays market.High price of the instrumentation will reduce the return on investments (ROI) owing to low adaptation.

For example, Biotek developed HCA (high content analysis) instruments and are expensive and reserved for industrial end-users or core labs which have sufficient capital budgets. This restricts the low budgeted end-users to use cell based assays to its full potential, thereby hampering the growth of the market.

In April 2019, PerkinElmer, a global corporation for diagnostics, life science research, food, environmental and industrial testing acquired Cisbio Bioassays for an undisclosed amount.The acquisition expands PerkinElmer’s R&D capability in cell based assay, and customer base in key growth geographies including the Americas, Europe, and China in order to expand its market reach for reagents.

Cisbio Bioassays is a custom assay service provider based in Codolet, France and was founded in 1974.

Research with cell based arrays is increasing with evolution and there is a definite need to move to more predictive cellular models for drug discovery in order to control the last-stage drug failures.The pharmaceutical industries’ need to efficiently commercialize drugs in order to overcome expensive failures in the last stages is a driving force in cell-based assay innovation.

Failure of investigational new drug (IND) Phase III clinical trials results in a loss of several hundred million dollars to that company.For instance, according to report by Sigma, the return on investment for pharmaceutical companies could drop to 5% considering the current level of late-stage failures, and is an unacceptable level for most companies.

Major improvements to high-content systems and data analysis from the cell based assays enable scientists to extract a more information about the cellular response and help take informed decisions during drug discovery, and further driving the market for cell based arrays.

Researchers are inclining towards early phase predictive toxicity testing that prevent late-stage drug failures.Predictive cell toxicity assays are being scaled up to increase screening of compounds in the early phases of drug development, reducing the cost of failure.

For instance, Creative Bioarray, a biotech company provides a range of in vitro toxicity services to check drug-induced toxicities that save time and cost by reducing the chance of failure in earlier stage. These advances will make clinical testing easy and reduce the cost of operation.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.